Compare Costco Wholesale Corporation (COST) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Ginkgo Bioworks Holdings Inc — how do they compare? Costco Wholesale Corporation trades at $949.23 (market cap $418.79B), while Ginkgo Bioworks Holdings Inc trades at $7.45 (market cap $505.73M). The key difference: Costco Wholesale Corporation is far larger — about 828.1× Ginkgo Bioworks Holdings Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| COST | DNA | |
|---|---|---|
Market Cap | $418.79B | $505.73M |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $16.14 |
52-Week Low | $849.63 | $5.48 |
Enterprise Value | $406.93B | $607.68M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $948.1, down 0.49% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $275.24B in 2025 and net income of $8.10B, though it missed Q1 2026 EPS estimates. Recent news highlights March sales up 11.3% year-over-year and institutional buying activity, while the stock remains near its 52-week high of $1,067.08.
Outlook is supported by robust membership fee growth and expansion, but high valuation ratios like a P/E of 47.5 pose risks. Analyst consensus is bullish with a $1,120 price target, though competitive pressures and economic sensitivity could challenge margins. The stock offers long-term growth potential if valuation aligns with earnings momentum.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
